/
DWTX
$1.78+$0.13 (+7.88%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$55.5M
34M shares
52-week range
$1.28 – $9.50
6% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.53%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.05
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $854.1K | $800.6K | $194.0K | $10.8M | $8.1M | $1.7M | $3.5M | $21.9M |
| Operating income | −$2.0M | −$2.2M | −$10.0M | −$15.6M | −$12.3M | −$5.4M | −$12.2M | −$28.0M |
| EBITDA | −$2.0M | −$2.2M | −$10.0M | −$16.0M | −$12.2M | −$5.3M | −$12.2M | −$34.0M |
| Net income | −$2.1M | −$2.5M | −$10.3M | −$16.0M | −$12.2M | −$5.3M | −$12.3M | −$34.3M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -10.93 | -12.80 | -52.50 | -47.90 | -27.66 | -7.05 | -12.52 | -4.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $129M | $-0.58 | $-0.60–$-0.56 | 2 |
| 2027 | $19M | $-0.74 | $-0.83–$-0.65 | 2 |
| 2028 | $9M | $-0.74 | $-1.11–$-0.47 | 3 |
| 2029 | $57M | $-0.21 | $-0.21–$-0.21 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.69
Price
$1.78
Implied downside
-61%
Peer comparison
Dogwood Therapeutics, Inc. Common Stock
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
www.virios.com- Employees
- 8
- IPO / List date
- Dec 17, 2020
- HQ
- ALPHARETTA, GA
Held by traders on TradeandTell
No one on the platform currently holds DWTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in DWTX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DWTX yet.
